This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes a method for enhancing the anti-tumor efficacy of immune effector cells, such as CAR-T cells, by administering a nitric oxide synthase (NOS) inhibitor. The application, filed by inventors Marco Davila and Sae Bom Lee, aims to address primary resistance and relapse in patients with large B cell lymphoma (LBCL) treated with CAR-T cells, suggesting that anti-inflammatory macrophages suppress CAR-T cell function.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in CAR-T cell therapy and related pharmaceutical research. Companies involved in CAR-T cell development or the manufacturing of related therapeutics may find this disclosure relevant for competitive intelligence and R&D strategy. No immediate actions or deadlines are associated with this publication.